Skip to content

Vaerno

Active Private limited companyfounded 2021active for 4 yearsEdgard Tinellaan 7, 2630 AartselaarKBO/BCE: BE 0778.733.519

Lifetime

4 annual accounts with figures on one time axis
peak of €289,700 in 2024
€277,969▼ 4.0%
peak of €206,412 in 2024
€196,638▼ 4.7%
peak of €307,427 in 2024
€4,000▼ 98.7%
€345,959▲ 211%
Board1 name since 2021
1 director
Documentsfilings and deeds
06-01-202625 days before the deadline
2025micro format
Dividend €500,065Equity from €307,427 to €4,000Debts from €111,202 to €345,959

Key points

from the 2025 annual accounts

Equity

€4,000 from €307,427 in 2024

Equity fell by 99% in 1 year.

Turnover

≈ €420,000 estimated

The micro format states no turnover.

Debts

€345,959 99% of the balance sheet
Financial debts 5%Taxes and wages 2%Other 93%

Of this, €328,114 falls due within a year.

Liquidity

0.91 was 4.09 in 2024

Short-term debts rose from €85,038 to €328,114.

Filings

4 annual accounts since 2022
deadline2022202320242025

The last four annual accounts were filed 5 to 60 days before the end of the period.

Position in the sector

1.1%

Lower solvency than 94% of companies in human health. Sector median 63.1% · 21,368 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,155 companies had the same profile as Vaerno has now. Each dot stands for 6 companies, two years later.

94.1%
were still trading
2.8%
stopped another way
3.0%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,155 companies, not a prediction for Vaerno. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 15-12-2021
  • 100 sharesdeed of 20-12-2021
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0778733519
Registered office moved from Antwerp to Aartselaar The registered office moved from Gallaitlaan 42 bus 5, 2610 Antwerpen to Edgard Tinellaan 7, 2630 Aartselaar · Board meeting of 25-07-2022 · Gazette deed
Incorporation Founding capital of €4,000, 100 shares · Founded by · appointed as director · published on 20-12-2021 · Gazette deed
First establishment At the time the registered office was still in Antwerpen.
All 11 events

Comparable companies

same main activity, similar in size and age
Company
Vaerno Aartselaar €349,959 €277,969 1.1% -
Dr. Hannelore Raemen Antwerp €393,412 €265,729 1.9% -
DR GRANDJEAN ALEXANDRE ANESTHESIE Gesves €381,840 €274,864 43.3% -
JV Endocrino Waregem €335,433 €269,467 79.4% -
Dr. Hannes Ruymbeke Temse €389,419 €252,826 99.5% -
Dr. Mathias Cottenie Bruges €338,516 €321,503 0.7% -
Dr. Van Bulck -  NKO Schilde €380,106 €247,274 27.6% -

These companies have the same main activity as Vaerno: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €335,000 and €393,000, founded between 2021 and 2022.

Official details

Source: KBO
Status
Active since 16-12-2021Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.325.137.9062630 Aartselaar, registered on 16-12-2021
Financial year end
30 June
Peppol
Reachable since 24-11-2023
Company details

Annual accounts to 30-06-2025

€349,959▼ 16.4%
Filing
Filed on 06-01-2026, 25 days before the end of the filing period
Financials

Insights on Vaerno

Vaerno files the micro format. That format states no turnover. The gross margin rose from €95,258 in 2022 to €277,969 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Vaerno

What is the company number of Vaerno?
The company number of Vaerno is 0778.733.519. The VAT number is the same number with BE in front: BE 0778.733.519.
Where is Vaerno based?
The registered office is at Edgard Tinellaan 7, 2630 Aartselaar.Company details
What does Vaerno do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of Vaerno?
Vaerno is a private limited company (BV).
When was Vaerno founded?
Vaerno was founded on 16-12-2021.
Is Vaerno still active?
Yes, Vaerno is an active enterprise in the KBO register.
What is the turnover of Vaerno?
The turnover in financial year 2025 is ≈ €420,000. This figure is estimated from the gross margin of €277,969 and 31 comparable companies (NACE 86220). It probably lies between €370,000 and €580,000.Financials
Is Vaerno profitable?
In financial year 2025, Vaerno made a profit of €196,638.
Where can I find the annual accounts of Vaerno?
Vaerno filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Vaerno due?
Vaerno must file the annual accounts for financial year 2026 by 31-01-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.